HOME >> BIOLOGY >> NEWS
Want to petrify wood without waiting a few million years? Try this

RICHLAND, Wash.--California has Silicon Valley. Could a Silicon Forest in Washington be next? A team of materials scientists from Pacific Northwest National Laboratory is on it.

Yongsoon Shin and colleagues at the Department of Energy lab have converted wood to mineral, achieving in days what it takes nature millions of years to do in such places as the Gingko Petrified Forest, an hour up the Columbia River. There, trees likely felled in a cataclysmic eruption and, buried without oxygen beneath lava, leached out their woody compounds and sponged up the soil's minerals over the eons.

Shin's petrified wood journey began in a less dramatic fashion, a few minutes away at Lowe's, Shin's group reports in the current issue of the journal Advanced Materials, in the do-it-yourselfer chain's lumberyard,. There they picked up their raw material: pine and poplar boards. Back at PNNL, they gave a 1 centimeter cube of wood a two-day acid bath, soaked it in a silica solution for two more (for best results, repeat this step up to three times), air-dried it, popped it into an argon-filled furnace gradually cranked up to 1,400 degrees centigrade to cook for two hours, then let cool in argon to room temperature.

Presto. Instant petrified wood, the silica taking up permanent residence with the carbon left in the cellulose to form a new silicon carbide, or SiC, ceramic. The material "replicates exactly the wood architecture," according to Shin.

Although SiC chips are unlikely to replace computer chips, materials scientists are interested in the novel properties of ceramics built on templates of wood and, in Shin's lab, other natural materials such as pollen and rice hulls. The intricate network of microchannels and pores in plant matter provide enormous surfaces--in wood, 1 gram of material flattened out would cover a football field--that may prove useful in industrial chemical separations or filtering pollutants from gaseous effluents.

The acid-
'"/>

Contact: Bill Cannon
cannon@pnl.gov
509-375-3732
DOE/Pacific Northwest National Laboratory
24-Jan-2005


Page: 1 2

Related biology news :

1. Coming soon -- Protein synthesis without amino acids?
2. Research without borders: Head of Santa Fe Institute to address NSF
3. 2-protein team would be lost without each other
4. Preventing cancer without killing cells
5. Moral judgment fails without feelings
6. Study: Chest compressions without mouth-to-mouth better for out-of-hospital cardiac arrest
7. Bacterium could treat PCBs without the need for dredging
8. New therapeutic target for Alzheimers could lead to drugs without side effects
9. Genetic hearing loss may be reversible without gene therapy
10. Cypress replanting unsuccessful without dual cultivation with lavender or mycorrhizal fungi
11. Preventing graft-versus-host disease disease after bone marrow transplant -- without toxicity

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Want petrify wood without waiting few million years Try this

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: